Aberdeen Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$54M Buy
983,048
+227,773
+30% +$12.5M 0.09% 193
2025
Q1
$53.4M Buy
755,275
+59,473
+9% +$4.2M 0.1% 180
2024
Q4
$45.7M Buy
695,802
+168,121
+32% +$11.1M 0.09% 219
2024
Q3
$37.1M Buy
527,681
+33,240
+7% +$2.34M 0.07% 260
2024
Q2
$40.7M Buy
494,441
+81,626
+20% +$6.72M 0.08% 242
2024
Q1
$36.1M Buy
412,815
+36,577
+10% +$3.19M 0.07% 258
2023
Q4
$36.3M Buy
376,238
+343,615
+1,053% +$33.1M 0.08% 257
2023
Q3
$2.89M Sell
32,623
-109
-0.3% -$9.64K 0.01% 645
2023
Q2
$2.84M Sell
32,732
-284
-0.9% -$24.6K 0.01% 675
2023
Q1
$3.21M Buy
33,016
+15,387
+87% +$1.5M 0.01% 654
2022
Q4
$1.82M Buy
17,629
+1,122
+7% +$116K 0.01% 713
2022
Q3
$1.4M Sell
16,507
-8,540
-34% -$724K ﹤0.01% 747
2022
Q2
$2.08M Buy
25,047
+1,989
+9% +$165K 0.01% 706
2022
Q1
$1.79M Buy
23,058
+2,849
+14% +$221K ﹤0.01% 752
2021
Q4
$1.79M Buy
20,209
+851
+4% +$75.2K ﹤0.01% 797
2021
Q3
$1.5M Buy
19,358
+3,431
+22% +$265K ﹤0.01% 833
2021
Q2
$1.33M Sell
15,927
-3,175
-17% -$265K ﹤0.01% 838
2021
Q1
$1.44M Buy
19,102
+405
+2% +$30.6K ﹤0.01% 814
2020
Q4
$1.64M Buy
18,697
+390
+2% +$34.2K ﹤0.01% 773
2020
Q3
$1.39M Sell
18,307
-5,112
-22% -$389K ﹤0.01% 756
2020
Q2
$2.89M Sell
23,419
-362
-2% -$44.7K 0.01% 644
2020
Q1
$2.01M Sell
23,781
-257
-1% -$21.7K 0.01% 667
2019
Q4
$2.03M Buy
24,038
+271
+1% +$22.9K ﹤0.01% 721
2019
Q3
$1.6M Buy
23,767
+892
+4% +$60.1K ﹤0.01% 741
2019
Q2
$1.96M Buy
22,875
+93
+0.4% +$7.97K ﹤0.01% 749
2019
Q1
$2.02M Buy
22,782
+13,433
+144% +$1.19M ﹤0.01% 734
2018
Q4
$785K Sell
9,349
-98
-1% -$8.23K ﹤0.01% 784
2018
Q3
$916K Sell
9,447
-355
-4% -$34.4K ﹤0.01% 810
2018
Q2
$923K Buy
+9,802
New +$923K ﹤0.01% 805